Yan Zhang Guo

8153626, Apr 10, 2012

Dec 7, 2007

12/517836

Robert K. Baker - Cranford NJ, US
Linda L. Chang - Wayne NJ, US
Marc Chioda - Metuchen NJ, US
Harry R. Chobanian - Aberdeen NJ, US
Yan Guo - Westfield NJ, US
Linus S. Lin - Westfield NJ, US
Ping Liu - Westfield NJ, US
Ravi P. Nargund - East Brunswick NJ, US
Kathleen M. Rupprecht - Cranford NJ, US
Shouwu Miao - Edison NJ, US

Merck Sharp & Dohme Corp. - Rahway NJ

A01N 43/62
A61K 31/55
C07D 491/00
C07D 513/00
C07D 515/00
C07D 243/10
C07D 487/12

514220, 540557

Certain novel substituted diazepine sulfonamides are ligands of the human bombesin receptor and, in particular, are selective ligands of the human bombesin receptor subtype-3 (BRS-3). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the modulation of BRS-3, such as obesity, and diabetes.

20110021531, Jan 27, 2011

Jul 27, 2009

12/509542

Harry CHOBANIAN - Aberdeen NJ, US
Linus S. Lin - Westfield NJ, US
Ping Liu - Westfield NJ, US
Marc D. Chioda - Metuchen NJ, US
Robert J. DeVita - Westfield NJ, US
Ravi P. Nargund - East Brunswick NJ, US
Yan Guo - Westfield NJ, US

A61K 31/497
C07D 413/14
A61K 31/444
A61K 31/501
A61P 25/00
A61P 19/00

51425203, 544405, 546256, 544238, 51425505, 514333

The present invention is directed to certain oxazole derivatives which are useful as inhibitors of Fatty Acid Amide Hydrolase (FAAH). The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzheimer Disease, and Parkinson's Disease.

20110144119, Jun 16, 2011

Jul 30, 2009

13/057415

Harry Chobanian - Aberdeen NJ, US
Linus S. Lin - Westfield NJ, US
Ping Liu - Westfield NJ, US
Marc D. Chioda - Metuchen NJ, US
Robert J. DeVita - Westfield NJ, US
Ravi P. Nargund - East Brunswick NJ, US
Yan Guo - Westfield NJ, US

A61K 31/501
C07D 413/14
A61K 31/497
C07D 413/04
A61K 31/444
A61K 31/4439
A61K 31/506
C07D 263/46
A61K 31/421
C07D 413/10
A61K 31/4245
C07D 413/12
A61K 31/4545
C07D 417/14
A61K 31/4725
A61K 31/4709
A61P 19/02
A61P 29/00
A61P 25/00
A61P 25/04
A61P 25/06
A61P 25/20
A61P 25/28
A61P 25/16

51425203, 544405, 51425505, 546256, 514333, 5462714, 514340, 544316, 514274, 548228, 514376, 548131, 514364, 544333, 514256, 544296, 546194, 514318, 544238, 5462697, 514342, 514341, 546141, 514309, 546167, 514314

The present invention is directed to certain oxazole derivatives which are useful as inhibitors of Fatty Acid Amide Hydrolase (FAAH). The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzeimer Disease, and Parkinson's Disease.

20130030000, Jan 31, 2013

Jan 25, 2011

13/574303

Harry R. Chobanian - Aberdeen NJ, US
Linus S. Lin - Westfield NJ, US
Ping Liu - Westfield NJ, US
Marc D. Chioda - New Brunswick NJ, US
Robert J. DeVita - Westfield NJ, US
Ravi P. Nargund - East Brunswick NJ, US
Yan Guo - Westfield NJ, US
Terence G. Hamill - Lansdale PA, US
Wenping Li - Lansdale PA, US
Darrell Arthur Henze - Collegeville PA, US

A61K 31/497
A61K 31/506
A61K 31/513
A61K 31/4439
A61K 31/421
A61K 31/4245
A61K 31/4545
A61K 31/501
A61K 31/4725
A61K 31/4709
A61P 29/00
A61P 25/22
A61P 3/04
A61P 27/02
A61P 11/06
A61P 27/06
A61P 9/00
A61P 25/24
A61P 43/00
A61P 19/02
A61P 25/28
A61P 25/18
A61P 25/30
A61P 25/16
A61P 25/08
A61P 11/00
A61P 35/00
A61P 1/00
A61P 1/04
A61P 1/12
A61P 17/04
A61P 1/16
A61P 25/06
A61P 25/02
A61K 31/444

51425203, 51425505, 514333, 514274, 514340, 514376, 514364, 514318, 514342, 514309, 514314, 514341, 514334

The present invention is directed to a composition useful for the treatment of a FAAH mediated disease, disorder or conditions comprising a FAAH inhibitor and a second activation, comprising a selected imidazole or oxazole FAAH inhibitor and a second active agent. The compositions will be useful in the treatment of a wide range of disease, disorder, or conditions including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzheimer disease, and Parkinson's disease. In another aspect the invention discloses herein is directed to compositions useful in the treatment of neuropathic and nociceptive pain, said compositions comprising etoricoxib.

20190337961, Nov 7, 2019

Dec 15, 2017

16/465156

- Rahway NJ, US
Harry R. Chobanian - Aberdeen NJ, US
Shuwen He - Fanwood NJ, US
Jinsong Hao - Belle Mead NJ, US
Barbara Pio - West Orange NJ, US
Yan Guo - Westfield NJ, US
Dong Xiao - Warren NJ, US

Merck Sharp & Dohme Corp. - Rahway NJ

C07D 491/107
C07D 311/96
C07D 405/12
A61P 3/10

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

20190071436, Mar 7, 2019

Mar 2, 2017

16/076781

- Rahway NJ, US
Wanying Sun - Edison NJ, US
Reynalda Keh Dejesus - East Brunswick NJ, US
Haifeng Tang - Metuchen NJ, US
Xianhai Huang - Warren NJ, US
Jinglong Jiang - Scotch Plains NJ, US
Yan Guo - Westfield NJ, US
Hongwu Wang - Westfield NJ, US

Merck Sharp & Dohme Corp. - Rahway NJ

C07D 417/14
A61P 31/04

The present invention relates to bicyclic aryl monobactam compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein A, L, M, W, X, Y, Z, Rand Rare as defined herein. The present invention also relates to compositions which comprise a bicyclic aryl monobactam compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The invention further relates to methods for treating a bacterial infection comprising administering to the patient a therapeutically effective amount of a compound of the invention, either alone or in combination with a therapeutically effective amount of one or more beta-lactamase inhibitor compounds.

20170275302, Sep 28, 2017

Oct 9, 2015

15/505266

Alexander PASTERNAK - Kenilworth NJ, US
Barbara PIO - Kenilworth NJ, US
Harry R. CHOBANIAN - Kenilworth NJ, US
Zhi-Cai SHI - Kenilworth NJ, US
Shuzhi DONG - Kenilworth NJ, US
Yan GUO - Kenilworth NJ, US
Shawn P. WALSH - Kenilworth NJ, US
Zhiqiang GUO - Rahway NJ, US
Ronald D. FERGUSON - Rahway NJ, US
Brian CATO - Secaucus NJ, US
- Rahway NJ, US

C07D 519/00
A61K 31/4985
C07D 471/10
A61K 31/435
C07D 498/10
A61K 31/519
A61K 31/437
A61K 31/4365
A61K 31/4375
A61K 31/4355
A61K 45/06
A61K 31/5025

The present invention provides compounds of Formula (I) and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.

20170217918, Aug 3, 2017

Aug 6, 2015

15/328735

Helen CHEN - Rahway NJ, US
Steven L. COLLETTI - Kenilworth NJ, US
Duane MONG - Kenilworth NJ, US
Yan GUO - Kenilworth NJ, US
Michael MILLER - Kenilworth NJ, US
Anilkumar NAIR - Kenilworth NJ, US
Christopher W. PLUMMER - Kenilworth NJ, US
Dong XIAO - Kenilworth NJ, US
De-Yi YANG - Kenilworth NJ, US
- Rahway NJ, US

C07D 311/60
C07D 405/14
C07D 471/08
C07D 487/08
C07D 487/04
C07D 491/107
C07D 413/12
C07D 491/08
C07D 405/10
C07D 491/048

Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.